Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

Similar articles for PubMed (Select 25001061)

1.

Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinoma.

Zheng X, Xing S, Liu XM, Liu W, Liu D, Chi PD, Chen H, Dai SQ, Zhong Q, Zeng MS, Liu WL.

BMC Cancer. 2014 Jul 7;14:490. doi: 10.1186/1471-2407-14-490.

2.

Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma.

Dong J, Zeng BH, Xu LH, Wang JY, Li MZ, Zeng MS, Liu WL.

J Transl Med. 2010 Sep 3;8:81. doi: 10.1186/1479-5876-8-81.

3.

[Clinical significance of serum high-mobility group box 1 detection in esophageal squamous cell carcinoma].

Chen CG, Cui L, Tang P, Yu ZT.

Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Sep;16(9):838-41. Chinese.

PMID:
24061989
4.
5.

Comparative evaluation of serum C-reactive protein (CRP) levels in the different histological subtypes of esophageal cancer (squamous cell carcinoma and adenocarcinoma of esophagus).

Lukaszewicz-Zając M, Mroczko B, Kozłowski M, Nikliński J, Laudański J, Siewko M, Szmitkowski M.

J Clin Lab Anal. 2012 Feb;26(2):73-81. doi: 10.1002/jcla.21486.

PMID:
22467322
6.

Higher importance of interleukin 6 than classic tumor markers (carcinoembryonic antigen and squamous cell cancer antigen) in the diagnosis of esophageal cancer patients.

Łukaszewicz-Zając M, Mroczko B, Kozłowski M, Nikliński J, Laudański J, Szmitkowski M.

Dis Esophagus. 2012 Apr;25(3):242-9. doi: 10.1111/j.1442-2050.2011.01242.x. Epub 2011 Sep 2.

PMID:
21895853
7.

Prognostic significance of CYFRA21-1, CEA and hemoglobin in patients with esophageal squamous cancer undergoing concurrent chemoradiotherapy.

Zhang HQ, Wang RB, Yan HJ, Zhao W, Zhu KL, Jiang SM, Hu XG, Yu JM.

Asian Pac J Cancer Prev. 2012;13(1):199-203.

8.

An expression of squamous cell carcinoma antigen 2 in peripheral blood within the different stages of esophageal carcinogenesis.

Yang YF, Li H, Xu XQ, Diao YT, Fang XQ, Wang Y, Zhao DL, Wu K, Li HQ.

Dis Esophagus. 2008;21(5):395-401. doi: 10.1111/j.1442-2050.2007.00789.x.

PMID:
19125792
9.

CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma.

Yi Y, Li B, Wang Z, Sun H, Gong H, Zhang Z.

Biomarkers. 2009 Nov;14(7):480-5. doi: 10.3109/13547500903180265.

PMID:
19863186
10.

Elevated levels of serum metalloproteinase 9 in patients with esophageal squamous cell carcinoma.

Łukaszewicz-Zajac M, Mroczko B, Kozłowski M, Nikliński J, Laudański J, Szmitkowski M.

Pol Arch Med Wewn. 2009 Sep;119(9):558-63.

11.

Serum SCCA, Cyfra 21-1, EGFR and Cyclin D1 levels in patients with oral squamous cell carcinoma.

Feng XY, Li JH, Li JZ, Han ZX, Xing RD.

Int J Biol Markers. 2010 Apr-Jun;25(2):93-8.

PMID:
20586028
12.

[Significance of CEA, SCC and Cyfra21-1 serum test in esophageal cancer].

Mao YS, Zhang DC, Zhao XH, Wang LJ, Qi J, Li XX.

Zhonghua Zhong Liu Za Zhi. 2003 Sep;25(5):457-60. Chinese.

PMID:
14575569
13.
14.

Preoperative Cyfra21-1 and SCC-Ag serum titers predict survival in patients with stage II esophageal squamous cell carcinoma.

Cao X, Zhang L, Feng GR, Yang J, Wang RY, Li J, Zheng XM, Han YJ.

J Transl Med. 2012 Sep 21;10:197. doi: 10.1186/1479-5876-10-197.

15.

Cytokeratin 19 fragment antigen 21-1 as an independent predictor for definitive chemoradiotherapy sensitivity in esophageal squamous cell carcinoma.

Yan HJ, Wang RB, Zhu KL, Jiang SM, Zhao W, Xu XQ, Feng R.

Chin Med J (Engl). 2012 Apr;125(8):1410-5.

PMID:
22613644
16.

[Diagnostic application of detecting AgNOR in peripheral blood T lymphocyte in patients with esophageal carcinoma].

Wang JY, Rong TH, Liang YR, Long H, Chen QL, Ma GW.

Ai Zheng. 2004 May;23(5):577-80. Chinese.

PMID:
15142458
17.

Combination assay for tumor markers in oral squamous cell carcinoma.

Kurokawa H, Yamashita Y, Tokudome S, Kajiyama M.

J Oral Maxillofac Surg. 1997 Sep;55(9):964-6.

PMID:
9294507
18.

Increased serum midkine concentration as a possible tumor marker in patients with superficial esophageal cancer.

Shimada H, Nabeya Y, Okazumi S, Matsubara H, Kadomatsu K, Muramatsu T, Ikematsu S, Sakuma S, Ochiai T.

Oncol Rep. 2003 Mar-Apr;10(2):411-4.

PMID:
12579281
19.

Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma.

Hirajima S, Komatsu S, Ichikawa D, Takeshita H, Konishi H, Shiozaki A, Morimura R, Tsujiura M, Nagata H, Kawaguchi T, Arita T, Kubota T, Fujiwara H, Okamoto K, Otsuji E.

Br J Cancer. 2013 May 14;108(9):1822-9. doi: 10.1038/bjc.2013.148. Epub 2013 Apr 11.

20.

YKL-40 expression in human hepatocellular carcinoma: a potential biomarker?

Xiao XQ, Hassanein T, Li QF, Liu W, Zheng YH, Chen J.

Hepatobiliary Pancreat Dis Int. 2011 Dec;10(6):605-10.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk